PharmaShots | Incisive News in 3 Shots

Subscribe Now

Akeso

Akeso Reports First Patient Enrollment in P-III Study of Ivonescimab + CT to Treat Triple-Negative Breast Cancer (TNBC) in China

Akeso Reports First Patient Enrollment in P-III Study of Ivonescimab + CT to Treat Triple-Negative Breast Cancer (TNBC) in China

February 21, 2025

Akeso Completes Patient Enrollment in P-III (HARMONi-6/AK112-306) Trial of Ivonescimab for Squamous NSCLC

Akeso Completes Patient Enrollment in P-III (HARMONi-6/AK112-306) Trial of Ivonescimab for Squamous NSCLC

February 6, 2025

China’s NMPA Accepts NDA for Akeso’s Gumokimab to Treat Moderate to Severe Psoriasis

China’s NMPA Accepts NDA for Akeso’s Gumokimab to Treat Moderate to Severe Psoriasis

January 27, 2025

Akeso Highlights the P-II Trial Data of Perioperative Ivonescimab for NSCLC at WCLC 2024

Akeso Highlights the P-II Trial Data of Perioperative Ivonescimab for NSCLC at WCLC 2024

September 9, 2024

Akeso Reports Positive Results of Cadonilimab in P-III study for the treatment of Cervical Cancer

Akeso Reports Positive Results of Cadonilimab in P-III study for the treatment of Cervical Cancer

November 28, 2023

Akeso Published P-Ia/Ib Study (COMPASSION-01) Results of Cadonilimab for Solid Tumors in Cell Reports Medicine

Akeso Published P-Ia/Ib Study (COMPASSION-01) Results of Cadonilimab for Solid Tumors in Cell Reports Medicine

October 20, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us